Tick-borne encephalitis vaccine - Pfizer

Drug Profile

Tick-borne encephalitis vaccine - Pfizer

Alternative Names: FSME-IMMUN Junior; FSME-IMMUN NEW; FSME-IMMUNE; TicoVac; TicoVac Junior

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hyland Immuno
  • Developer Hyland Immuno; Pfizer
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Encephalitis virus infections

Most Recent Events

  • 30 Jul 2014 Pfizer signs a definitive agreement to acquire tick-borne encephalitis vaccine from Baxter
  • 17 Feb 2004 A clinical study has been added to the adverse events and Viral Infections immunogenicity sections
  • 21 Jun 2002 New formulation registered for Encephalitis virus infections in Germany (injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top